<div><div></div><div>Natural's Michael E. Fortin will resign as Chief Financial Officer effective May 15, 2026, and Kenneth E. Wolf will act as Principal Financial and Principal Accounting Officer while the company seeks a replacement.<div><table><tbody><tr><td>Individual</td><td>Michael E. Fortin</td><td>Kenneth E. Wolf</td></tr><tr><td>Role</td><td>Chief Financial Officer</td><td>President; Acting Principal Financial and Principal Accounting Officer</td></tr><tr><td>Type of Change</td><td>Resigned</td><td>Appointed (acting)</td></tr><tr><td>Effective Date</td><td>May 15, 2026</td><td>While company seeks replacement (effective immediately)</td></tr><tr><td>Reason</td><td>Accepted CFO role at another company with increased responsibilities and opportunities</td><td>Not disclosed</td></tr><tr><td>Replacement Info</td><td>Company seeking a replacement Chief Financial Officer</td><td>N/A</td></tr><tr><td>Background Details</td><td>Not disclosed</td><td>Formerly served as the Company's Chief Financial Officer; currently President</td></tr><tr><td>Board/Committee Role Changes</td><td>Not disclosed</td><td>Not disclosed</td></tr></tbody></table></div>Original SEC Filing: NATURAL ALTERNATIVES INTERNATIONAL INC [ NAII ] - 8-K - May. 01, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

NAII

LABU

Natural's CFO Michael E. Fortin will resign effective May 15, 2026, to accept a new role at another company. Kenneth E. Wolf will serve as Acting Principal Financial and Principal Accounting Officer while the company searches for a replacement. The change is effective immediately, but the reason for Fortin's departure is due to increased responsibilities and opportunities at the new position. Details regarding the replacement process have not been disclosed.

TradingView

Natural Alternatives

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Ark Genomic Revolution ETF

SPDR S&P Biotech

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Pharma

VanEck Biotech ETF

Natural's Michael E. Fortin to Resign as CFO; Kenneth E. Wolf to Serve as Acting Principal Financial Officer